WorldSouth China Morning Post
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
Read the full story at South China Morning Post
China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market.
China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults.
GLP-1 receptor agonists are synthetic...
More world
- अमेरिकी डलरको भाउ बढ्यो, अरू विदेशी मुद्राको मूल्य थप घट्योNepal Khabar
- Bengal Church attacks: Choosing faith over fearThe Hindu
- Mind the gap: Partial opening of Namma Metro Pink Line leaves commuters wantingThe Hindu
- UAE says 14 killed, 30 injured in Fujairah traffic accidentThe Hindu
- Lutnick Took a Softer Line on Nvidia as Calls for Tougher Controls GrewThe New York Times
- Sriperumbudur toll plaza gets MLFFThe Hindu